sintilimab   Click here for help

GtoPdb Ligand ID: 12990

Synonyms: IBI 308 | IBI-308 | IBI308 | Tyvyt®
Approved drug Immunopharmacology Ligand
sintilimab is an approved drug (China (2018))
Compound class: Antibody
Comment: Sintilimab (IBI 308) is a fully human IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [5]. It acts as an immune checkpoint inhibitor and is used clinically as an immuno-oncology therapeutic.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
Sintilimab binds weakly to rabbit PD-1 and does not bind to mouse or rat PD-1 [5]. It inhibits binding of PD-L1 to PD-1 on CHO cells with an IC50 of ~4μg/ml.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Binding 9.6 pKd - 5
⤷ pKd 9.6 (Kd 2.5x10-10 M) [5]
programmed cell death 1 (CD279) Monkey Antibody Binding 9.4 pKd - 5
⤷ pKd 9.4 (Kd 4.5x10-10 M) [5]